Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6Myeloid 5Thoracic 4Head & Neck 3Genitourinary 2Sarcoma 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pioglitazone × Endocrine × Clear all
NCT01655719 2017-10-26

Pioglitazone in Thyroid Cancers

University of Michigan

Phase 2 Completed
1 enrolled 6 charts
EndocrineHead & Neck

Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene

Data powered by HemOnc (CC BY 4.0) Colophon âš¡